Pollara, G; Bali, S; Marks, M; Bates, I; Collier, S; Balakrishnan, I (2017) Time efficiency assessment of antimicrobial stewardship strategies. Clinical infectious diseases. ISSN 1058-4838 DOI: 10.1093/cid/cix220

Downloaded from: http://researchonline.lshtm.ac.uk/3682745/

DOI: 10.1093/cid/cix220

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
We appreciate the concern raised by Ozaras et al regarding the hepatitis B surface antibody (anti-HBs) status of the 103 hepatitis C virus (HCV)–infected patients who were hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive and had no evidence of hepatitis B virus (HBV) reactivation during or following treatment with ledipasvir/sofosbuvir [1, 2]. To address this concern, we retrospectively determined the anti-HBs status of the 103 patients who were positive for anti-HBc, by analyzing archived samples using the ADVIA Centaur Anti-HBs Reagent Kit (Siemens Healthcare Diagnostics, Tarrytown, New York). Of 103 patient samples analyzed, 37 (36%) were anti-HBs negative, 63 (61%) were anti-HBs positive, and 3 (3%) could not be evaluated because the remaining samples were inadequate. Of the 2 patients identified in our initial analysis as being HBsAg negative and anti-HBc positive with detectable HBV DNA below the lower limit of quantification, both were found to be negative for anti-HBs. Importantly, none of the 37 anti-HBc–positive/HBs-negative patients experienced HBV reactivation in our study, including the 2 patients with detectable HBV DNA.

Published case reports suggest that clinical HBV reactivation is a rare occurrence. The majority of described cases occurred in persons who were HBsAg positive, indicative of active HBV infection. Some of these patients may have met criteria for HBV treatment prior to the initiation of HCV therapy. In the case series reported by Bersoff-Matcha and colleagues from the US Food and Drug Administration, the status of HBV infection was incomplete for many patients, which limits the interpretation of the risk of HBV flare, particularly among those reported to be HBsAg negative [3]. Liu and colleagues presented data in 2016 on HBV reactivation in 134 patients receiving DAA treatment for HCV [4]. Of the 134 patients, 81 patients were HBsAg negative and anti-HBc positive. No evidence of HBV reactivation was observed in these 81 patients, which is consistent with our findings. The precise risk of HBV reactivation is difficult to estimate, but the relatively high global prevalence of HBV infection in persons with chronic HCV infection and the small number of cases of HBV reactivation or alanine aminotransferase flare reported among the >1 million persons treated with direct-acting antivirals (DAAs) for HCV suggest that the risk is low [5].

We believe that HCV-infected patients should be screened for HBV infection prior to initiation of DAsAAs and, for those found to have active HBV infection, HBV treatment guidelines should be followed. Given the benefits of successful HCV treatment, the risk of HBV reactivation should not be overstated.

Notes

Financial support. This work was supported by Gilead Sciences.

Potential conflicts of interest. M. S. S. has received research grants from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck, and personal fees from AbbVie, Gilead, Janssen, Cocrystal, Merck, and Trek. D. M. B. and J. C. Y. are employees of and hold stock interest in Gilead. E. J. G. has received research grants from Gilead Sciences; has served on advisory boards for AbbVie, Boehringer Ingelheim, Gilead Sciences, Janssen, Novartis, Roche, and Tibotec; and has served on the speaker’s bureaus for Gilead Sciences, Novartis, Roche, and Tibotec. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Mark S. Sulkowski,1 Diana M. Brainard,2 Jenny C. Yang,3 and Edward J. Gane3

1 Johns Hopkins University School of Medicine, Baltimore, Maryland; 2 Gilead Sciences, Foster City, California; and 3 New Zealand Liver Transplant Unit, Auckland City Hospital

References

form of PPRF that most efficiently impacts inappropriate antimicrobial prescribing [5, 6].

We performed a prospective, observational study that compared different forms of PPRF: ward round reviews on acute medical wards, ward round reviews on surgical recovery wards, and telephone reviews with clinical teams caring for patients receiving carbapenems, cephalosporines, or quinolones. Each stewardship review episode was performed by 2 microbiologists and a pharmacist, who collected no more data than needed for routine practice and were not aware that the data would be used comparatively in the study. The 3 stewardship modalities occurred daily for 45, 90, or 60 minutes—for medical rounds, surgical rounds, and telephone reviews, respectively—and there was no overlap in the patients reviewed. All antimicrobial prescriptions reviewed were quantified and any intervention was recorded, with an intervention defined as a change to antimicrobial prescription, including starting or stopping treatment with a medication or modifying the duration of treatment or mode of administration. For the purpose of comparison, we considered telephone stewardship to be the control group. We calculated both the proportion of reviews resulting in an intervention and the rate of interventions per hour of stewardship time. Both approaches were significantly better than telephone stewardship in terms of both the proportion and rate of stewardship interventions. We propose that other hospitals looking to assess and prioritize the impact of their stewardship programs should also incorporate a standardized time-based measure of stewardship efficiency.

**Table 1. Number, Proportion and Rate of Interventions by Stewardship Modality**

<table>
<thead>
<tr>
<th>Stewardship Approach</th>
<th>Prescriptions Reviewed, No.</th>
<th>Stewardship Interventions</th>
<th>Intervention Rate, Interventions per Hour of Stewardship (95% CI)</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telephone</td>
<td>691</td>
<td>30 (4.34)</td>
<td>0.48 (.34–.69)</td>
<td></td>
</tr>
<tr>
<td>Medical round</td>
<td>802</td>
<td>75 (9.35)</td>
<td>2.26 (1.8–2.83)</td>
<td>4.69 (3.07–7.17)</td>
</tr>
<tr>
<td>Surgical round</td>
<td>435</td>
<td>162 (37.24)</td>
<td>1.70 (1.36–1.98)</td>
<td>3.53 (2.39–5.21)</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.

Notes

Financial support. This work was supported by the Wellcome Trust (grant WT101766/Z/13/Z to G. P.).

Potential conflicts of interest. Author certifies no potential conflicts of interest. All author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Gabriele Pollara, Suparna Bali, Michael Marks, Ian Bates, Sophie Collier, and Indran Balakrishnan

Departments of Microbiology and Pharmacy, Royal Free London, Division of Infection and Immunity, University College London, University College London School of Pharmacy, and Clinical Research Department, London School of Hygiene and Tropical Medicine, United Kingdom

References


Optimizing Proton Pump Inhibitor Use to Reduce Antimicrobial Resistance Rates?

To the Editor—With the greatest interest we read the study of Huizinga and colleagues on the impact of proton pump inhibitor (PPI) use on colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae [1]. In our multicenter Antibiotic Therapy Optimization Study (ATHOS), the study group obtained rectal swabs of 4376 patients on hospital admission and determined the prevalence for